ReviewTrends in immunology2025
Infusion of neutralization into Lassa vaccine design.
Review in Trends in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lassa virus (LASV), which causes deadly Lassa fever (endemic in Western Africa), is a priority pathogen and a global health threat. Current vaccine candidates protect LASV-challenged animals through T cell immunity or non-neutralizing IgG/Fc receptor-mediated functions in the absence of potent neutralization. Neutralizing antibodies (nAbs), applied through passive immunization, also provide broad and complete protection against LASV. Rational design of LASV glycoprotein complex (GPC), the primary target for adaptive immunity, overcomes prior challenges to elicitation of nAbs caused by the dense glycan shield, metastability, and heterogeneity of GPC. Well-engineered GPC immunogens, in combination with advanced immunization methods and existing clinical trial phase vaccine candidates, provide a possibility to infuse neutralizing activity into complementary mechanisms of immune protection delivered by LASV vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.